Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Arrowhead Pharmaceuticals develops RNA interference-based therapeutics using its proprietary TRiM™ platform. The company has a broad and advancing clinical pipeline targeting cardiometabolic diseases and rare genetic disorders. Its lead program plozasiran has shown positive pivotal Phase 3 results in familial chylomicronemia syndrome. Several partnered programs are also progressing toward late-stage development or commercialization.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Arrowhead Regional Development Corporation.